Kees BeenCEO & President Lysosomal Therapeutics
Alastair BrownHead of Pharmacology Heptares Therapeutics
Craig FerrisDirector, Centre for Neurotranslational Imaging Northeastern University
Paul McGonigleHead, Drug Discovery & Development Program Drexel University
Following the success of previous meetings, this year we have researched with the CNS community to bring you a meeting which will focus on providing you with the key information to improve the predictive validity of preclinical models and biomarkers to ensure drug safety and efficacy before these drugs are moved to trials.
Designed to build on the collaboration of previous years and drive the forward movement for the industry, the leading drug developers will be here, sharing their honest insights and experiences. Attend and you will discover new ways to progress your pipeline and tap into the huge commercial opportunity CNS diseases represent.
Attendees will meet with commercial and academic leaders to inspire new ideas and strategies to help minimize clinical attrition, maximize pipeline potential and see a return on investments made in the CNS field.
Attendees will learn how to:
Discover the technologies and techniques that are proving beneficial to drug development and avoid the approaches that have historically led to failure.
“The talks were high quality and the interaction among the participants was excellent”
“Great organization, agenda, speaker panel, audience – I couldn’t have asked for anything more!” Scannexus
“The conference was an excellent size where optimal discussion occurredand the presentations were of high quality” Envivo Pharma
“ Overall an excellent meeting. Thanks.” AMRI
“The speakers tried to emphasize specific strategies to overcome shortcomings in recent drug development history. This differentiates the summit.” Partner HealthCare